Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- befree-2016 importedOn "2016-02-19" NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_assertion wasGeneratedBy ECO_0000203 NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_assertion wasDerivedFrom befree-2016 NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_assertion SIO_000772 24206575 NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_assertion evidence source_evidence_literature NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.
- NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_assertion description "[Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1126414.RA4ucvxRDekP_fnS9iH8g4yy8AQQp5YQtO3OrQ5u1NsS8130_provenance.